Protein engineering finds application in the areas of food and detergent manufacturing, environmental bioremediation, medicine, biopolymer production, nanobiotechnology and industrially important enzyme production.
The global protein engineering market is driven by rising prevalence of protein deficient chronic diseases and the demand for alternatives to chemical processes. However, the market is constrained due to lack of experts to strategize the process and huge costs of the process.
The global protein engineering market can be segmented by end user: biotechnology companies, pharmaceutical companies, academic institutions, and contract research organisations (CRO); by product type: modified proteins, insulin, monoclonal antibodies, modified enzymes, blood factors, tissue plasminogen activator and fusion proteins; and by technology: irrational protein design and rational protein design.
The global protein engineering market has also been geographically segmented into Asia Pacific, Europe, Middle East and North Africa (MENA), North America and Rest of the World, with North America dominating the global market. Asia Pacific is also an emerging market which has a scope for growth and can potentially dominate the market in the future.
The growth of protein engineering market globally is majorly associated to the increasing prevalence of the use of protein engineering in healthcare institutes and hospitals. The major companies dominating this market with its products, services, and continuous product developments are Eli Lilly, Novo Nordisk, Roche, Biogen, Amgen, Fusion Antibodies, Genzyme, and Abbott. However, capitalisation on patents is a major challenge faced by the market players.
Market analysis for the global protein engineering market, with region specific assessments and competition analysis on global and regional scales.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market shares.
Identification and analysis of the macro and micro factors that affect the protein engineering market on both global and regional scales.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Characterisation
5.1 Current Market Scenario
5.2 Market Overview
5.3 Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis
5.3.1 Market Drivers
22.214.171.124 Increasing Prevalence of Protein Deficient Diseases
126.96.36.199 Increased Demand for Alternatives to Chemical Processes
5.3.2 Market Restraints
188.8.131.52 Lack of Experts to Strategize the Process
184.108.40.206 High Costs
5.3.3 Market Challenges
220.127.116.11 Capitalisation on Patents
5.3.4 Market Opportunities
18.104.22.168 Increasing Use of Protein Engineering in Healthcare Institutions and Hospitals
5.4 Neonatal & Prenatal Devices Market Segmentation
5.4.1 By End User
22.214.171.124 Biotechnology Companies
126.96.36.199 Pharmaceutical Companies
188.8.131.52 Academic Institutions
184.108.40.206 Contract Research Organisations (CRO)
5.4.2 By Product Type
220.127.116.11 Modified Proteins
18.104.22.168 Modified Enzymes
22.214.171.124 Monoclonal Antibodies
126.96.36.199 Blood Factors
188.8.131.52 Tissue Plasminogen Activator
184.108.40.206 Fusion Proteins
5.4.3 By Technology
220.127.116.11 Irrational Protein Design
18.104.22.168 Rational Protein Design
5.4.4 By Geography
22.214.171.124 Asia Pacific
126.96.36.199 Middle East & North Africa (MENA)
188.8.131.52 North America
184.108.40.206 Rest of the World
6. Industry Analysis
6.1 Key Trends and Developments
6.2 Investment Analysis
6.3 Porter’s Five Forces
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Power of Consumers
6.3.3 Threat of New Entrants
6.3.4 Threat of Substitute Products and Services
6.3.5 Competitive Rivalry within the Industry
7. Competitive Landscape
7.1 Key Market Players
7.1.1 Abbott Healthcare
220.127.116.11 Abbott Healthcare- Business Overview
18.104.22.168 Abbott Healthcare- Product and Services Portfolio
22.214.171.124 Abbott Healthcare- Deals Landscape
126.96.36.199 Abbott Healthcare- SWOT Analysis
7.1.2 Eli Lilly
7.1.3 Novo Nordisk
7.1.7 Fusion Antibodies
7.2 Merger and Acquisition Analysis
7.3 New Product Launches
7.4 Agreements, Collaborations & Partnerships
8. Analyst Outlook for Investment Opportunities
9. Future Outlook of the Market